FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220986469> ?p ?o ?g. }

• W4220986469 endingPage "01" @default.
• W4220986469 startingPage "P3" @default.
• W4220986469 abstract "Abstract Background: To estimate the long-term consequences of disease recurrence following treatment with adjuvant T-DM1 among U.S. patients with high-risk HER2+ ESBC who did not achieve pathologic complete response (pCR) after neoadjuvant therapy. Methods: A Markov model was used to simulate local/regional and distant recurrence with 10 years of follow-up. This corresponds to the estimated number of U.S. patients with incident high-risk HER2+ ESBC in 2021 (n = 10,000), which was derived from SEER population-based estimates, the NEOSPHERE trial and expert clinical opinion. The probability of recurrence was based on the T-DM1 arm in the KATHERINE trial and long-term results from the HERA trial. We assumed that 80% of patients with any recurrence experience distant recurrence, while the remainder have local/regional recurrence. SEER data and literature review were used to estimate probabilities of survival, distant recurrence secondary to local/regional recurrence, and direct medical costs. We estimated indirect costs were equal to 15% of direct medical costs. Model outcomes included: recurrences, breast cancer-related deaths, non-breast cancer-related deaths, direct medical costs, and indirect costs (all undiscounted). Results were compared to a scenario in which there was no recurrence to estimate population impact. All outcomes were also projected over 10 annual incident cohorts, each with 10 years of follow-up. Results: We estimated the 2021 U.S. patient cohort would experience 2,279 recurrences, including 1,834 distant, and 1,559 breast cancer-related deaths over 10 years, resulting in 7,744 lost years of life and $632 million in additional spending, including $549 million in direct medical costs. Projection to 10 years of incident cohorts would lead to approximately 23,000 recurrences, 16,000 deaths, 77,000 lost years of life and $6 billion in direct medical costs. Conclusions: Patients with HER2+ ESBC who do not achieve pCR after neoadjuvant therapy are at ongoing risk of recurrence despite the effectiveness of treatment with T-DM1. There is substantial clinical and economic value in further reducing the recurrence risk among this population. Findings for 2021 Cohort Projected over 10 YearsWith recurrenceNo recurrenceDifferenceLocal/regional recurrences4450445Distant recurrence1,83401,834Breast cancer deaths1,55901,559Non-breast cancer deaths416457-41Direct costs$573M$24M$549MIndirect costs$86M$3.6M$82MLife years90,24997,993-7,744Costs$659M$27M$632M Citation Format: David L Veenstra, Nathaniel Hendrix, Chantal M Dolan, Kathryn Fisher, Deepa Lalla, Nina Hill, Beverly Moy. Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-16-01." @default.
• W4220986469 created "2022-04-03" @default.
• W4220986469 creator A5017550097 @default.
• W4220986469 creator A5024882579 @default.
• W4220986469 creator A5041075056 @default.
• W4220986469 creator A5052256740 @default.
• W4220986469 creator A5067278845 @default.
• W4220986469 creator A5072015843 @default.
• W4220986469 creator A5085042140 @default.
• W4220986469 date "2022-02-15" @default.
• W4220986469 modified "2023-10-04" @default.
• W4220986469 title "Abstract P3-16-01: Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)" @default.
• W4220986469 doi "https://doi.org/10.1158/1538-7445.sabcs21-p3-16-01" @default.
• W4220986469 hasPublicationYear "2022" @default.
• W4220986469 type Work @default.
• W4220986469 citedByCount "0" @default.
• W4220986469 crossrefType "journal-article" @default.
• W4220986469 hasAuthorship W4220986469A5017550097 @default.
• W4220986469 hasAuthorship W4220986469A5024882579 @default.
• W4220986469 hasAuthorship W4220986469A5041075056 @default.
• W4220986469 hasAuthorship W4220986469A5052256740 @default.
• W4220986469 hasAuthorship W4220986469A5067278845 @default.
• W4220986469 hasAuthorship W4220986469A5072015843 @default.
• W4220986469 hasAuthorship W4220986469A5085042140 @default.
• W4220986469 hasConcept C121608353 @default.
• W4220986469 hasConcept C126322002 @default.
• W4220986469 hasConcept C141071460 @default.
• W4220986469 hasConcept C143998085 @default.
• W4220986469 hasConcept C146357865 @default.
• W4220986469 hasConcept C151730666 @default.
• W4220986469 hasConcept C2778527826 @default.
• W4220986469 hasConcept C2908647359 @default.
• W4220986469 hasConcept C530470458 @default.
• W4220986469 hasConcept C71924100 @default.
• W4220986469 hasConcept C72563966 @default.
• W4220986469 hasConcept C86803240 @default.
• W4220986469 hasConcept C99454951 @default.
• W4220986469 hasConceptScore W4220986469C121608353 @default.
• W4220986469 hasConceptScore W4220986469C126322002 @default.
• W4220986469 hasConceptScore W4220986469C141071460 @default.
• W4220986469 hasConceptScore W4220986469C143998085 @default.
• W4220986469 hasConceptScore W4220986469C146357865 @default.
• W4220986469 hasConceptScore W4220986469C151730666 @default.
• W4220986469 hasConceptScore W4220986469C2778527826 @default.
• W4220986469 hasConceptScore W4220986469C2908647359 @default.
• W4220986469 hasConceptScore W4220986469C530470458 @default.
• W4220986469 hasConceptScore W4220986469C71924100 @default.
• W4220986469 hasConceptScore W4220986469C72563966 @default.
• W4220986469 hasConceptScore W4220986469C86803240 @default.
• W4220986469 hasConceptScore W4220986469C99454951 @default.
• W4220986469 hasIssue "4_Supplement" @default.
• W4220986469 hasLocation W42209864691 @default.
• W4220986469 hasOpenAccess W4220986469 @default.
• W4220986469 hasPrimaryLocation W42209864691 @default.
• W4220986469 hasRelatedWork W2003938723 @default.
• W4220986469 hasRelatedWork W2017990408 @default.
• W4220986469 hasRelatedWork W2047967234 @default.
• W4220986469 hasRelatedWork W2076790491 @default.
• W4220986469 hasRelatedWork W2113427382 @default.
• W4220986469 hasRelatedWork W2118496982 @default.
• W4220986469 hasRelatedWork W2332192242 @default.
• W4220986469 hasRelatedWork W2439875401 @default.
• W4220986469 hasRelatedWork W4238867864 @default.
• W4220986469 hasRelatedWork W2525756941 @default.
• W4220986469 hasVolume "82" @default.
• W4220986469 isParatext "false" @default.
• W4220986469 isRetracted "false" @default.
• W4220986469 workType "article" @default.